Reduce tremor using brain stimulation
- Trial ID
- NCT07574164
- Official Title
- Transcranial Magnetic Stimulation for the Treatment of Tremo
- Goal
- Reduce tremor using brain stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of Oxford
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Essential Tremor, Parkinson's Disease (PD)
- Interventions
- TMS
Summary For Families
They're testing whether transcranial magnetic stimulation can reduce tremor severity in people with essential tremor or Parkinson's disease. TMS uses brief magnetic pulses over the scalp to change activity in the brain circuits that generate tremor, aiming to lower tremor amplitude; it is non-invasive and not a drug, so it does not directly alter levodopa or other Parkinson's medications and can be used alongside them. Adults 18 and older with essential tremor or Parkinson's can join, while anyone with contraindications to brain stimulation, for example certain metal implants or a history of seizures, will be excluded. The small study plans to enroll about 20 people and is run by the University of Oxford.
Locations
- Oxford Center for Integrative Neuroimaging, Oxford, Oxfordshire, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying TMS. They're testing whether transcranial magnetic stimulation can reduce tremor severity in people with essential tremor or Parkinson's disease. TMS uses brief magnetic pulses over the scalp to change activity in the brain circuits that generate tremor, aiming to lower tremor amplitude; it is non-invasive and not a drug, so it does not directly alter levodopa or other Parkinson's medications and can be used alongside them. Adults 18 and older with essential tremor or Parkinson's can join, while anyone with contraindications to brain stimulation, for example certain metal implants or a history of seizures, will be excluded. The small study plans to enroll about 20 people and is run by the University of Oxford.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.